Cantor A - Search Results

1

Osteopontin identified as colon cancer tumor progression marker.

Agrawal D, Chen T, Irby R, Quackenbush J, Chambers AF, Szabo M, Cantor A, Coppola D, Yeatman TJ. Agrawal D, et al. Among authors: cantor a. C R Biol. 2003 Oct-Nov;326(10-11):1041-3. doi: 10.1016/j.crvi.2003.09.007. C R Biol. 2003. PMID: 14744111 Free article.

2

Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling.

Agrawal D, Chen T, Irby R, Quackenbush J, Chambers AF, Szabo M, Cantor A, Coppola D, Yeatman TJ. Agrawal D, et al. Among authors: cantor a. J Natl Cancer Inst. 2002 Apr 3;94(7):513-21. doi: 10.1093/jnci/94.7.513. J Natl Cancer Inst. 2002. PMID: 11929952

3

Molecular staging for survival prediction of colorectal cancer patients.

Eschrich S, Yang I, Bloom G, Kwong KY, Boulware D, Cantor A, Coppola D, Kruhøffer M, Aaltonen L, Orntoft TF, Quackenbush J, Yeatman TJ. Eschrich S, et al. Among authors: cantor a. J Clin Oncol. 2005 May 20;23(15):3526-35. doi: 10.1200/JCO.2005.00.695. J Clin Oncol. 2005. PMID: 15908663

4

Loss of nuclear p21(Cip1/WAF1) during neoplastic progression to metastasis in gamma-irradiated p21 hemizygous mice.

Engelman RW, Jackson RJ, Coppola D, Wharton W, Cantor AB, Pledger WJ. Engelman RW, et al. Exp Mol Pathol. 2007 Jun;82(3):234-44. doi: 10.1016/j.yexmp.2006.10.007. Epub 2007 Jan 4. Exp Mol Pathol. 2007. PMID: 17207793 Free PMC article.

5

Bilaterality and recurrence rates for lobular breast cancer: considerations for treatment.

Yeatman TJ, Lyman GH, Smith SK, Reintgen DS, Cantor AB, Cox CE. Yeatman TJ, et al. Among authors: cantor ab. Ann Surg Oncol. 1997 Apr-May;4(3):198-202. doi: 10.1007/BF02306610. Ann Surg Oncol. 1997. PMID: 9142379

6

p21Cip1 nullizygosity increases tumor metastasis in irradiated mice.

Jackson RJ, Engelman RW, Coppola D, Cantor AB, Wharton W, Pledger WJ. Jackson RJ, et al. Cancer Res. 2003 Jun 15;63(12):3021-5. Cancer Res. 2003. PMID: 12810620

7

Loss of the cell cycle inhibitors p21(Cip1) and p27(Kip1) enhances tumorigenesis in knockout mouse models.

Jackson RJ, Adnane J, Coppola D, Cantor A, Sebti SM, Pledger WJ. Jackson RJ, et al. Among authors: cantor a. Oncogene. 2002 Dec 5;21(55):8486-97. doi: 10.1038/sj.onc.1205946. Oncogene. 2002. PMID: 12466968

8

Role of p53, CD44V6 and CD57 in differentiating between benign and malignant follicular neoplasms of the thyroid.

Nasir A, Catalano E, Calafati S, Cantor A, Kaiser HE, Coppola D. Nasir A, et al. Among authors: cantor a. In Vivo. 2004 Mar-Apr;18(2):189-95. In Vivo. 2004. PMID: 15113046 Free article.

9

CD44V6 expression in human colorectal carcinoma.

Coppola D, Hyacinthe M, Fu L, Cantor AB, Karl R, Marcet J, Cooper DL, Nicosia SV, Cooper HS. Coppola D, et al. Among authors: cantor ab. Hum Pathol. 1998 Jun;29(6):627-35. doi: 10.1016/s0046-8177(98)80014-2. Hum Pathol. 1998. PMID: 9635685

10

Tumor biology of infiltrating lobular carcinoma. Implications for management.

Yeatman TJ, Cantor AB, Smith TJ, Smith SK, Reintgen DS, Miller MS, Ku NN, Baekey PA, Cox CE. Yeatman TJ, et al. Among authors: cantor ab. Ann Surg. 1995 Oct;222(4):549-59; discussion 559-61. doi: 10.1097/00000658-199522240-00012. Ann Surg. 1995. PMID: 7574934 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

571 results

Search Page

Filters